
Opinion|Videos|June 9, 2025
The MOA of TLX250
Panelists discuss how the new tracing agent (Zr-DFO-girentuximab or 2050) works by binding to carbonic anhydrase IX, an enzyme expressed on the surface of most clear cell renal cancers, coupled with zirconium for radiographic detection.
Advertisement
Episodes in this series

The Novel Tracer 89Zr-TLX250
Main Discussion Topics:
- 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX).
- CAIX is an enzyme expressed on the surface of most clear cell renal cell carcinomas (ccRCCs).
- The antibody is coupled to zirconium-89, a positron emitter detectable on PET imaging.
Key Points for Physicians:
- The tracer targets CAIX, which is highly expressed in ccRCC.
- The mechanism of action involves antibody binding coupled with a radioactive tracer.
- Zirconium-89 serves as the positron-emitting component for detection.
Notable Insights:
The targeting of CAIX represents a specific molecular approach to identifying ccRCC based on its unique expression pattern.
Clinical Significance:
This targeted molecular approach represents a fundamental shift from anatomic to biological characterization of renal masses.
Advertisement
Related to this article

Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
4
The UroOnc Minute: The Role of Language in Cancer Care, With Jessica Rett, PhD
5


